Hemington Wealth Management Summit Therapeutics Inc. Transaction History
Hemington Wealth Management
- $691 Million
- Q2 2025
A detailed history of Hemington Wealth Management transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Hemington Wealth Management holds 93 shares of SMMT stock, worth $2,590. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93
Previous 68
36.76%
Holding current value
$2,590
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
248Shares Held
87.6MCall Options Held
1.77MPut Options Held
2.49M-
Baker Bros. Advisors LP New York, NY24.4MShares$680 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$324 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$220 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$183 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$135 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...